Glauconix Biosciences Promotes Kimberly Southern to Chief Executive Officer

Source: Glauconix Biosciences

Glauconix Biosciences announced that its board of directors has appointed Kim Southern as Chief Executive Officer and a member of the Board of Directors effective immediately. Ms. Southern previously held the position of Chief Operating Officer.

Since joining the company in May, Ms. Southern has further developed the corporate vision and strategy—most notably the company’s decision to focus on the development of additional bioengineered human 3D tissue models to support needs beyond glaucoma. The company has plans to expand their patented technology to additional ocular tissues and other areas of significant unmet need such as lung, kidney, and skin tissue.

“Since joining the company in May of 2019, as COO, Kim has demonstrated a willingness to roll up her sleeves to strengthen the operation of the company, develop a long-term strategy and grow the team allowing the founder Karen Torrejon to focus on the continued development of the game changing technology. The board is pleased to elevate her to the position of CEO,” Richard Frederick, Board Member, said in a company news release.

Karen Torrejon, PhD, Founder and CSO, will manage and execute the company’s development efforts.

“Over the last 6 months working side by side with Kim, it is clear to me that her vision, integrity and ability to leverage the strengths of the team, align with the core mission of the company,” Dr. Torrejon said. “I am very excited and look forward to spending more of my time on further expansion of our core technology while Kim focuses on the implementation and execution of our vision.”

“I am extremely excited about Kim’s appointment to CEO of Glauconix,” Robert Dempsey, Board Member, said in the news release. “Her business acumen, attention to financial details and strategic vision have all been on display since joining the organization. These skills, along with her leadership ability, will be critical to transform the company to the next phase of growth in ophthalmology and other potential business segments”

“Glauconix Biosciences is one of those companies that has a unique platform technology that supports expansion into many different markets, and I am honored to have been chosen to lead the company,” Ms. Southern said. “The opportunity ahead for us is significant, but to maximize it, we must focus clearly, and continue to innovate. A big part of my job is to accelerate our ability to develop additional models and bring them to the market more quickly.”

Related Content